UCB reports positive data from phase III Vimpat study

UCB has announced encouraging clinical trial data that support the safety and efficacy of its drug Vimpat in the treatment of epilepsy.

Data from the US-based trial showed a positive performance in terms of efficacy and safety when converting to Vimpat monotherapy among adult patients with partial-onset seizures with or without secondary generalisation compared with a historical control.

The trial met its primary efficacy endpoint, with the exit rate for patients on the lacosamide-based therapy proving to be significantly lower than the control treatment.

UCB will use these results to support a planned new drug application for Vimpat in the second half of 2013.

Professor Dr Iris Loew-Friedrich, chief medical officer and executive vice-president of UCB, said: "We are very pleased with these top-line results and look forward to discussing the detailed study results with the regulatory agencies and the scientific community."

In 2012, international sales of Vimpat increased by 53 percent on the previous year, proving a major driver of growth for UCB.